Project Grant R01CA292507
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$552K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports research to investigate the role of the transcription factor SOX9 in the development of gastric cancer. The $142,020 award to Vanderbilt University aims to elucidate the functional and transcriptional mechanisms by which SOX9 regulates the formation of spasmolytic polypeptide-expressing metaplastic (SPEM) cells, which are essential for the progression of gastric...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) provides $154,642 to the Sloan-Kettering Institute for Cancer Research to elucidate the evolving immunopeptidome of metastatic colorectal cancer. The award aims to systematically identify conserved intracellular targets derived from fetal-like gene expression programs in colorectal tumors that could serve as therapeutic interventions. Additionally, the project will...
The National Cancer Institute (NCI) awarded a $560,297 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Icahn School of Medicine at Mount Sinai. The grant, with a project period from September 1, 2024 to August 31, 2029, will fund research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The research aims to determine the molecular drivers of the ONFSCS and their role in CRC progression and treatment resistance, as well as...
This is a Project Grant award from the National Cancer Institute under the Cancer Treatment Research Federal Grant Program (CFDA 93.395) to The General Hospital Corporation (doing business as Massachusetts General Hospital) for $697,629 from June 14, 2024 to May 31, 2029. The funding supports research to develop covalent small molecule inhibitors targeting the transcription factor SOX10, which is required for the proliferation of over 85% of melanoma models. The research aims to: 1) define the...
The National Cancer Institute (NCI) awarded a five-year, $491,826 Project Grant (CFDA 93.396 - Cancer Biology Research) to The University of Texas Southwestern Medical Center (UT Southwestern) to investigate the role of the testis-specific serine kinase 6 (TSSK6) gene in colorectal cancer. The research aims to comprehensively study how the aberrant expression of this normally testes-restricted gene influences tumor cell invasion, metastasis, viability, and chemoresistance. The project will...
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research a $205,700 Project Grant (CFDA 93.395 Cancer Treatment Research) from March 1, 2025 to February 28, 2027. The grant will fund research to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer, and test a novel combination approach to prevent the emergence of resistance. Key research activities include deep analysis of clinical samples, cell...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program CFDA 93.395 "Cancer Treatment Research", is funding a $640,583 research project at Cold Spring Harbor Laboratory (CSHL) to enhance the efficacy of immunotherapy against metastatic colorectal cancer (MCRC). The key objective is to activate the PPARD-CPT1A axis in CD8+ T cells, thereby promoting mitochondrial fatty acid oxidation to boost the fitness and anti-tumor activity of these...
The Project Grant award R01CA296618, totaling $523,292.00, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The award, effective from December 4, 2024 to November 30, 2029, supports research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) to investigate the molecular mechanisms by which the microhomology-mediated end-joining (MMEJ) DNA repair pathway is suppressed in Ewing sarcoma, a rare and...
This Project Grant award of $942,442 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by the Dana-Farber Cancer Institute (DFCI) to identify the mechanisms driving the rapid evolution of cancer genomes. The key objectives are to understand the processes of chromothripsis, a catastrophic mutational event involving massive chromosome rearrangement, and chromoplexy, another poorly understood mutational process common in cancer. Using...